A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 45/06 (2006.01) A61K 31/19 (2006.01) A61K 31/195 (2006.01) A61K 31/4166 (2006.01) A61K 31/55 (2006.01) A61P 3/10 (2006.01)
Patent
CA 2430309
This invention relates to pharmaceutical compositions comprising combinations of a GABA agonist, a prodrug thereof or a pharmaceutically acceptable salt of said GABA agonist or said prodrug and an ARI, a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug, kits containing such combinations and methods of using such combinations to treat mammals, including humans, suffering from diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic retinopathy, diabetic microangiopathy, diabetic macroangiopathy, cataracts or foot ulcers.
La présente invention concerne des compositions pharmaceutiques à base de combinaisons entre d'une part un GABA-agoniste, l'un de ses promédicaments, ou l'un sel pharmaceutiquement admis dudit GABA-agoniste ou dudit promédicament, et d'autre part un ARI, l'un de ses promédicaments ou l'un des sels pharmaceutiquement admis dudit ARI ou dudit promédicament. L'invention concerne également des nécessaires contenant de telles combinaisons. L'invention concerne enfin des procédés permettant d'utiliser de telles combinaisons pour le traitement de mammifères, y-compris humains, atteints de complications diabétiques telles que neuropathie diabétique, néphropathie diabétique, cardiomyopathie diabétique, rétinopathie diabétique, microangiopathie diabétique, macro-angiopathie diabétique, cataractes ou l'ulcère variqueux.
Pfizer Products Inc.
Smart & Biggar
LandOfFree
Combination of gaba agonists and aldose reductase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of gaba agonists and aldose reductase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of gaba agonists and aldose reductase inhibitors will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1978375